MHRA
The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 3 June 2025, approved aumolertinib (Aumseqa) for adult patients with non-small cell lung cancer (NSCLC). Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor (EGFR) and who have not yet received treatment for […]
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved polihexanide (Akantior) to treat acanthamoeba keratitis. Acanthamoeba keratitis is an infection of the cornea, the clear ‘window’ at the front of the eye, that can be very painful. This medicine has been approved through the International Recognition Procedure (IRP). The IRP allows the MHRA to […]
Local Weather Forcast
-º
-
-
-
-
-
--
-
---
-
---
-
---
-
--Pages
